Entera Bio Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Entera Bio's estimated annual revenue is currently $3.6M per year.(i)
  • Entera Bio's estimated revenue per employee is $155,000

Employee Data

  • Entera Bio has 23 Employees.(i)
  • Entera Bio grew their employee count by 0% last year.

Entera Bio's People

NameTitleEmail/Phone
1
COOReveal Email/Phone
2
Head Clinical OperationsReveal Email/Phone
3
Head BioPharmaceutics and BioAnalyticsReveal Email/Phone
4
Production and R&D employeeReveal Email/Phone
5
Assistant ControllerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Entera Bio?

Entera Bio is a product-focused biotechnology company specializing in the oral delivery of large molecules and biologics. Entera Bio is currently conducting clinical trials on its proprietary technology which allows oral delivery of large molecules and biologics while enhancing their absorption in the GI tract. Entera Bio's technology addresses the two major problems of oral drug delivery of large molecule APIs (active pharmaceutical ingredients). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. Entera's Proprietary Technologies Act Synergistically to Transport and Protect Large Molecules.

keywords:N/A

N/A

Total Funding

23

Number of Employees

$3.6M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Entera Bio News

2022-04-19 - Hypoparathyroidism Treatment Market Size 2022-2029| Key ...

AbbVie; Entera Bio; GlaxoSmithKline; Roche; Sun Pharmaceutical; Takeda; Takeda Pharmaceutical; Teva Pharmaceuticals. Hypoparathyroidism...

2022-04-13 - Zacks: Analysts Expect Entera Bio Ltd. (NASDAQ:ENTX) to ...

Entera Bio posted earnings per share of ($0.43) in the same quarter last year, which indicates a positive year over year growth rate of 62.8%.

2022-03-22 - Entera Bio Reports Financial Results for the Year Ended ...

Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.8M23-32%N/A
#2
$4.7M230%N/A
#3
$2.3M23N/AN/A
#4
$1.7M23N/AN/A
#5
$2.3M23N/AN/A